Xbrane Biopharma AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xbrane Biopharma AB
The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.
Sweden’s Xbrane BioPharma has followed through on plans to tap the equity markets for cash to fuel the planned launch of its Ximluci (ranibizumab) biosimilar version of Lucentis in Europe.
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- Primm Pharma Srl